Miwa Haranaka

A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)

Heather Platt, José F. Cardona, Miwa Haranaka et al. · Vaccine · 2021 · 91 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine–Experienced Adults 50 Years of Age or Older (STRIDE-6)

Paul T. Scott, Miwa Haranaka, Jung‐Hyun Choi et al. · Clinical Infectious Diseases · 2024 · 33 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19

Junsaku Kitagawa, Hayato Arai, Hiroyuki Iida et al. · Clinical and Translational Science · 2021 · 31 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults

Miwa Haranaka, James Baber, Yoichiro Ogama et al. · Nature Communications · 2021 · 30 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Adult-onset Still’s disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept

Keisuke Maeshima, Koji Ishii, Mikako Iwakura et al. · Modern Rheumatology · 2011 · 26 citations

Life Sciences, Pharmacology, Pharmacotherapy +11